Harmony Biosciences Holdings Long Term Debt

Harmony Biosciences Holdings (HRMY) currently reports a long-term debt of $130M as of June 2026. That compares with $150M in the prior-year period — down 12.6% year over year. Use the charts on this page to explore Harmony Biosciences Holdings's long-term debt history and peer comparisons.

Harmony Biosciences Holdings's long-term debt decreased from $150M to $130M — a 12.6% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Harmony Biosciences Holdings reported $130M in long-term debt as of June 2026. That compares with $150M in the prior-year period — down 12.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $130M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Harmony Biosciences Holdings, and consider following HRMY for alerts when major investors trade the stock.

Harmony Biosciences Holdings is classified in the Healthcare sector. On long-term debt, it currently shows $130M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing HRMY with unrelated industries.